Maxim A. Bogdanov

Maxim A. Bogdanov

Auto-generated profile, based on publicly available information

Maxim A. Bogdanov

Northern State Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Ekologiya cheloveka (Human Ecology)
Verified
Journal Article
Open access
PDF file
MVMikhail Yu. Valkov
Mikhail Yu. Valkov
AGAndrej M Grjibovski
Andrej M Grjibovski
AKAlexander V. Kudryavtsev
Alexander V. Kudryavtsev
MBMaxim A. Bogdanov
Maxim A. Bogdanov
DBDmitriy V. Bogdanov
Dmitriy V. Bogdanov
ГАГомболевский Виктор Александрович
Гомболевский Виктор Александрович
Aim: To present the ARILIS study aimed at assessing the use of artificial intelligence to analyze chest computed tomography (CT) data to predict and prevent non-cancer mortality in patients with cancer. Material and methods: This cohort study will include patients with cancer diagnosed in the Arkhangelsk region (AR) within the 2019–2023 period. The COVID-19 patients with pneumonia, patients with general medical conditions, and the population of the Know Your Heart Study are planned to be enrolled as control groups. To detect and quantify the CT signs of the cardiovascular, pulmonary, and bone disorders, the thoracic СT scans of all the subjects will be processed using the multi-targeted AI algorithm provided by the IRA Labs company. From the date of processing of the thoracic CT scans using the multi-targeted AI algorithm, the study subjects will be followed for new clinical diagnoses and all-cause mortality. Expected results: T he study will determine the prevalence of CT signs of the cardiovascular, pulmonary, and bone disorders in patients with cancer compared with the Know Your Heart Study population sample. It will also assess the incidence of cardiovascular, pulmonary, and bone events and all-cause mortality in patients with cancer compared with control groups, explore the potential of the IRA Labs’ multi-targeted AI algorithm in the assessment and reclassification of assessed risks in patients with cancer, and provide a software product for using mtIA in healthcare practice.

17 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ADA.A. Dyachenko
A.A. Dyachenko
MBM.A. Bogdanov
M.A. Bogdanov
DBDmitriy V Bogdanov
Dmitriy V Bogdanov
AGAndrej M Grjibovski
Andrej M Grjibovski
AMA.A. Markov
A.A. Markov
MVMikhail Yu Valkov
Mikhail Yu Valkov
Background: Clinically manifested pneumonia associated with COVID-19 infection in cancer patients has been associated with worse prognosis. The prognostic significance of subclinical manifestations of pulmonary infiltration is poorly understood. Aims: To estimate the survival of cancer patients with signs of asymptomatic pneumonia detected by a multitarget artificial intelligence (AI) algorithm on chest computed tomography (CT) during the COVID-19 pandemic, and to evaluate factors associated with the risk of death in this population. Materials and methods: This population-based cohort study, conducted within the ARILUS project, included 1,147 examinations of cancer patients performed between August 2020 and May 2021. Signs of pneumonia on CT were detected by the AI algorithm in 556 (48.4%) patients with malignant neoplasms (MN) who had no clinical manifestations of infection at the time of the examination. Overall survival (OS) was assessed using the life table and Kaplan-Meier methods. Multivariate Cox proportional hazards regression analysis was used to identify independent predictors of death and to assess the influence of potential confounding factors. Results: During the follow-up period, 680 deaths were recorded among cancer patients, of which 575 deaths were due to MN progression. Three-year OS differed significantly between the groups: in patients without signs of pulmonary infiltration on CT, it was 60.7% (95% CI 56.6%– 64.7%), whereas in patients with AI-detected signs of pneumonia, it was 45.6% (95% CI 41.3%– 49.8%) (p<0.001). In the multivariable regression analysis, independent factors associated with an unfavorable prognosis (death) were: presence of pulmonary infiltration (adjusted hazard ratio (HR) 1.31; 95% CI 1.09–1.58), male sex (HR 1.25; 95% CI 1.00–1.57), and MN stage (HR 1.78 for stage II, HR 2.93 for stage III, and HR 4.74 for stage IV compared to stage I). Signs of pulmonary emphysema (HR 1.84), aortic aneurysm (HR 1.75), and coronary artery calcification (HR 1.22-1.34), which were significantly associated with the risk of death in the univariable analysis, lost their prognostic significance in the multivariable model after adjustment for other variables. Conclusions: Asymptomatic COVID-19 pneumonia detected by AI on CT is an independent predictor of reduced overall survival in MN patients. Automated AI screening for such changes may be recommended in routine practice.

31 July 2025 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
ADA. A. Dyachenko
A. A. Dyachenko
AGAndrej M Grjibovski
Andrej M Grjibovski
MBM. A. Bogdanov
M. A. Bogdanov
DBD. V. Bogdanov
D. V. Bogdanov
ENE. A. Nazarova
E. A. Nazarova
MVM. Yu. Valkov
M. Yu. Valkov
Aim. To study the prevalence of pneumonia features associated with 2019 coronavirus disease (COVID-19) in cancer patients based on chest computed tomography (CT) data using an artificial intelligence (AI) algorithm.Materials and methods. A cross-sectional study was conducted as part of the ARILUS project. Using multitarget AI, CT images of 1148 patients examined at the Arkhangelsk Clinical Oncology Dispensary from 01.04.2020 to 31.12.2021 were analyzed. Patients were divided into groups: without signs of pneumonia (n = 592, 51.6%) and with signs of pneumonia (n = 556, 48.4%). In 95.3% of patients with pneumonia, the lesion volume was less than 25% (CT-1). Using multivariate Poisson regression, adjusted prevalence ratios (aPR) with 95% confidence intervals (CI) were calculated.Results. For demographic characteristics such as gender, age, place of residence, no relationship with the presence of signs of COVID-19 pneumonia was established. Topography of neoplasm is associated with the presence of signs of COVID-19 pneumonia (reference group – cancers of the female genital organs): lung cancer – aPR 1.87; 95% CI: 1.40–2.49; head and neck cancers – aPR 1.85; 95% CI: 1.32–2.58; upper gastrointestinal tract – aPR 1.51; 95% CI: 1.12–2.04; breast cancer – aPR: 1.38; 95% CI: 1.00–1.90; p < 0.01. The presence of pulmonary emphysema is associated with signs of COVID-19 pneumonia: aPR 1.25; 95% CI: 1.09–1.45, p = 0.002. With an increase in the Agatston score (AS) reflecting coronary artery calcification (reference group absence of calcification), the association with the presence of signs of COVID-19 pneumonia increased – for AS 1–99: aPR 1.24; 95% CI: 1.05–1.47; AS 100– 299: aPR 1.58; 95% CI: 1.33–1.87; AS 300 and above: aPR 1.61; 95% CI: 1.36–1.90; p < 0.001 for a linear trend.Conclusion. Factors associated with the detection of COVID-19 pneumonia among cancer patients include the localization of neoplasms in the lungs, head and neck organs, upper gastrointestinal tract, breast, and as well as the presence of signs of emphysema and coronary calcification according to CT data

13 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ADAndrey A. Dyachenko
Andrey A. Dyachenko
MBMaxim A. Bogdanov
Maxim A. Bogdanov
DBDmitry V. Bogdanov
Dmitry V. Bogdanov
AMAnna A. Meldo
Anna A. Meldo
VCValeria Chernina
Valeria Chernina
MVMikhail Yu. Valkov
Mikhail Yu. Valkov
Background: Cancer patients face a significantly elevated risk of severe COVID-19 outcomes. Although vaccination is a cornerstone of prevention, data on vaccination coverage and association with survival among Russian cancer patients remain scarce. We assessed COVID-19 vaccination coverage and its association with overall survival in a population-based cohort of cancer patients in Northwest Russia. Methods: This retrospective registry-based cohort study integrated data from the Population-Based Cancer Registry (PBCR) of the Arkhangelsk Region and the Nenets Autonomous Okrug, regional vaccination records, and an artificial intelligence (AI)-based analysis of chest computed tomography (CT) scans. The cohort consisted of 1,144 cancer patients who underwent CT between August 2020 and April 2021. Vaccination status was ascertained via data linkage. Overall survival (OS) was compared between vaccinated and unvaccinated patients using Kaplan–Meier analysis and multivariable Cox proportional hazards regression, adjusted for demographic, clinical, and AI-derived CT biomarkers. To mitigate immortal time bias, the primary analysis used a landmark approach restricted to patients alive on March 1, 2021 (N = 1,136). A sensitivity analysis used a November 1, 2021 landmark (N = 894). Vaccination status was defined as receipt of at least one dose before the landmark date. Results: Only 6.6% (n=76) of patients received at least one dose of a COVID-19 vaccine (Sputnik V or Sputnik Light). Vaccinated patients were more likely to have earlier-stage cancer and were less likely to be receiving active treatment. In the primary landmark analysis, vaccination was associated with a significantly higher 3-year OS (80.3% vs. 45.7%, p < 0.001). In multivariable analysis, vaccination was independently associated with a 60% lower hazard of all-cause mortality (adjusted HR 0.40, 95% CI 0.25–0.64). AI-detected COVID-19 pneumonia on baseline CT was also an independent predictor of poorer survival (adjusted HR 1.32, 95% CI 1.09–1.59). In the sensitivity analysis (November 1, 2021 landmark), the adjusted HR for vaccination was 0.56 (95% CI 0.34–0.92), showing a consistent but attenuated association. Conclusion: This study reveals critically low COVID-19 vaccination coverage among cancer patients in Northwest Russia. Nevertheless, vaccination was strongly associated with a substantial survival benefit, underscoring its importance as a potentially lifesaving intervention for this vulnerable population.

11 September 2025 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
ДГДмитрий Дмитриевич Громов
Дмитрий Дмитриевич Громов
ПКПетр Андреевич Курчатов
Петр Андреевич Курчатов
ОАОксана Анатольевна Афиногенова
Оксана Анатольевна Афиногенова
МЗМария Андреевна Заярная
Мария Андреевна Заярная
МБМаксим Андреевич Богданов
Максим Андреевич Богданов
ВГВиктор Александрович Гомболевский
Виктор Александрович Гомболевский
Введение. В последние десятилетия отмечено снижение показателей смертности населения от злокачественных новообразований (ЗНО). Риск смерти больных ЗНО от других причин может значительно превышать таковой в популяции. Цель. На основе данных популяционного ракового регистра Архангельской области и Ненецкого автономного округа (ПРР АО и НАО) оценить частоту и динамику смерти больных раком 12 часто выявляемых ЗНО от неонкологических причин и оценить относительный риск смерти больных раком от неонкологических заболеваний в сравнении с общей популяцией. Материалы и методы. Данные о больных 12-ю инвазивными ЗНО, диагностированными в период с 2008 по 2023 гг., были извлечены из базы данных ПРР АО и НАО. Изучена динамика смертности от индексных ЗНО (иЗНО), неиндексных ЗНО, неонкологических причин для каждого из иЗНО. Рассчитаны стандартизованные по возрасту отношения смертности (СОС) больных ЗНО от сердечно-сосудистых (ССЗ) и респираторных заболеваний (РЗ) в сравнении с общей популяцией. Результаты. Проанализировано 51 076 случаев ЗНО. В течение анализируемого периода отмечалось значимое увеличение пропорции смертей от неонкологических причин с 8,9–33,2 % в 2008–2009 гг. до 4,5–47,2 % в 2022–2023 гг. Во время пандемии COVID-19 пропорция смертей от неопухолевой патологии возросла от 16,6 % при раке легкого до 58,0 % при раке предстательной железы, а доля смертей от РЗ возросла до 26,7 %. ССЗ лидировали среди неонкологических причин смерти, составляя до 66,5 % при раке предстательной железы в период 2022–2023 гг. Значения СОС от ССЗ увеличивались при всех иЗНО, наиболее значительно — при раке полости рта и шейки матки, до 10,0 (95 % ДИ 6,2–15,3) и 12,8 (95 % ДИ 8,5–18,3) в 2022–2023 гг. Относительный риск смерти от РЗ у больных иЗНО был более высоким относительно общей популяции в период пандемии COVID-19, достигая пика в 45–105 раз. Заключение. Установлено, что неонкологические заболевания являются важной составной частью общей смертности больных ЗНО, причем их доля возрастает. Относительный риск смерти пациентов с ЗНО от ССЗ и РЗ может быть на порядок выше общепопуляционного.